Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Doğan, Emine; Sever, Ozkan; Çakır, Burçin; Çelik, Erkan

doi:10.2147/opth.s162019

Cited by 8 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies from literature have shown significant improvement in RVO patients with SRD both functionally and morphologically. Dogen et al studied changes of central macular thickness and VA in BRVO patients with and without SRD after intravitreal ranibizumab injection and found SRD group showed greater improvement of macular morphology [13]. Pinazo et al evaluated response to ranibizumab of BRVO patients with and without SRD and found an improvement of + 15 letters of BCVA and − 205.9 μm of central foveal thickness in patients with SRD over a mean follow-up of 12.5 months.…”

Section: Discussionmentioning

confidence: 99%

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Chen

Yuan

Sun

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate choroid thickness and macular retinal metrics in treatment naïve retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter. Methods This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4-6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype. Results In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05). Conclusion Thicker choroid was a feature of naïve RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Chen

Yuan

Sun

et al. 2020

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In addition, a more marked improvement of macular structure was achieved in patients with SRD than in those without SRD. These ndings may be explained by the strong association of in ammatory factors and extensive morphological changes with the occurrence and/or recurrence of SRD, thus patients with SRD have better improvement of macular structure by anti-VEGF treatment [13]. Based on previous reports and the current study, we suggest that if SRD is observed only at the rst presentation, it does not necessarily predict poor visual prognosis because anti-VEGF treatment can alleviate damage to foveal photoreceptors in the outer segment by restoring the ELM barrier and improving macular structure and function [15].…”

Section: Discussionmentioning

confidence: 99%

“…Photoreceptor damage is more likely to occur with prolonged and/or repeated severe retinal edema. From short-term studies, patients who had SRD at initial presentation tended to have worse visual acuity during the follow-up [13]. Broken retinal capillaries lead to sub-retinal uid, thickening the retina.…”

Section: Discussionmentioning

confidence: 99%

Treatment strategy for BVO-ME based on long-term outcomes correlating retinal structure by OCT image and visual acuity

Fujiwara

Mori

Kimura

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose: Intravitreal anti-vascular endothelial growth factor (VEGF) is a mainstream treatment for reducing ME secondary to BRVO (BVO-ME）. Regrettably, most reports of intravitreal anti-VEGF for BVO-ME have disclosed only short-term outcomes. Here, we characterized long-term indicators for the visual prognosis of patients with BVO-ME, including the correlation between retinal structure by OCT and visual acuity. Methods: Patients with BVO-ME were retrospectively recruited based on clinical records in Kansai Medical University Hospital from June 2012 to March 2022. Patients were divided into two groups according to BCVA at the final visit: Group A (≥0.7) and Group B (≤0.6). Results: 47 eyes from 45 patients were assessed. The mean follow-up period from initial to final visit was 64.38 ± 15.07 (range, 38-100) months. BCVA in Group A (n = 32) was significantly greater than in Group B (n = 15) at all timepoints. The ratio that the number of eyes which the EZ band and the foveal bulge were intact in Group A was higher than in Group B (p = 0.0004 and p = 0.0002, respectively). The ratio that the number of eyes which recurrence SRD was observed by the final visit in Group A was lower than in Group B (p = 0.0485). Conclusion: The integrity of the EZ band and an intact foveal bulge were significant predictors for visual acuity. In contrast, recurrent SRD led to poor visual acuity in the long term, even if BCVA was good in the short term.

show abstract

“…По нашим предположениям, данный факт может быть связан не только с истинной толщиной, но и с часто встречающейся ОНЭ, которая автоматически увеличивает высоту макулярного отека. На исходно бóльшую толщину сетчатки в фовеа у пациентов с наличием ОНЭ указывали и другие авторы [24][25][26].…”

Section: обсуждение результатовunclassified

Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy

Khokhlova

Лоскутов²

2021

Oftalʹmologiâ

View full text Add to dashboard Cite

Purpose: to establish the tomographic parameters to predict the recurrent of macular edema due to retinal vein occlusion.Patients and methods. This is a retrospective study of 54 patients (54 eyes) with macular edema, no more than 3 months old, who had recurrent of macular edema after 3 intravitreal injections of aflibercept. Standard ophthalmological examination, spectral optical coherence tomography, intravitreal injections of aflibercept according to instruction, and statistical analysis of the data were conducted.Results. Recurrence of macular edema developed on average 6.3 ± 1.2 weeks after three injections of aflibercept. We identified of the most significant prognostic tomographic parameters affecting the recurrent of macular edema during intravitreal injections of aflibercept — central foveal thickness > 500 μm (OR 2.1, p = 0.01), the presence of serous retinal detachment (OR 5.1, p = 0.001), the presence of hyperreflective foci (OR 3.7, p = 0.03), alteration of external limiting membrane (OR 4.7, p = 0.01), disruption of the photoreceptor innersegment/outer segment junction (OR 3.4, p = 0.01), disruption of retinal pigment epithelium (OR 2.1, p = 0.02).Conclusion: the recurrent of macular edema with retinal vein occlusion during antiangiogenic therapy depends on baseline tomographic parameters. Our results can be important in predicting the duration and effectiveness of antiangiogenic therapy in a particular patient at the beginning of the disease, which makes the approach to management more personalized, promising in economic, social and psychological aspects.

show abstract

Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion

Cited by 8 publications

References 33 publications

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Choroidal thickening in retinal vein occlusion patients with serous retinal detachment

Treatment strategy for BVO-ME based on long-term outcomes correlating retinal structure by OCT image and visual acuity

Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy

Contact Info

Product

Resources

About